M Monami, B Cresci, A Colombini, L Pala, D … - Diabetes Care, 2008 - Am Diabetes Assoc OBJECTIVE—Hypoglycemic treatments could modulate the risk for fractures in
many ways. Most studies have not explored the effect on the incidence of bone
fractures of individual oral hypoglycemic agents, rather all oral ... Cited by 17 - Related articles - BL Direct - All 8 versions
S Dagdelen, D Sener, M Bayraktar - Advances in Therapy, 2007 - Springer Bisphosphonates are effective agents for postmenopausal osteoporosis, but their
efficacy in patients with type 2 diabetes mellitus (DM) is not known. The
investi- gators evaluated bone mineral density (BMD) response to ... Cited by 4 - Related articles - BL Direct - All 2 versions
[CITATION] ADOPT Study Group. Rosiglitazone Associated fractures in type 2 diabetes: an analysis …
- ►endojournals.org Z Berberoglu, A Gursoy, N Bayraktar, AC … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Objectives: Our objectives were to evaluate the effect of rosiglitazone on bone
metabolism and to assess the association between changes in bone turnover
parameters and plasma cytokine levels in postmenopausal diabetic women. Cited by 23 - Related articles - BL Direct - All 4 versions
J Seufert, R Urquhart - Diabetes Research and Clinical Practice, 2007 - Elsevier Adult patients with Type 2 diabetes took part in one of two large-scale, 2-year
clinical trials. One study compared pioglitazone treatment as add-on to failing
metformin therapy (N = 317) with add-on gliclazide treatment to metformin ... Cited by 8 - Related articles - All 18 versions
- ►oxfordjournals.org [PDF] M Janghorbani, RM Van Dam, WC Willett, FB … - American Journal of Epidemiology, 2007 - Oxford Univ Press 1 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan
University of Medical Sciences, Isfahan, Iran. 2 Department of Nutrition,
Harvard School of Public Health, Boston, MA. 3 Channing Laboratory, ... Cited by 34 - Related articles - BL Direct - All 10 versions
AV Schwartz, DE Sellmeyer - Expert Opin. Drug Saf., 2008 - informahealthcare.com Rosiglitazone and pioglitazone are associated with increased fracture risk in
women, and, for rosiglitazone, more rapid bone loss. Negative skeletal effects
of these thiazolidinediones (TZDs) have also been observed in animal and in ... Cited by 23 - Related articles - BL Direct - All 5 versions
[CITATION] Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type …
